Here are the top 5 articles for the month of November.
Hi, this is Laura Joszt for The American Journal of Managed Care®. Here are the top 5 articles for the month of November.
Number 5: Data presented at the 2019 American Heart Association Scientific Sessions may have answered how a purified fish oil pill reduces cardiovascular events. The research suggests the pill helps slow the advance of various coronary plaques.
Number 4: At the American Society of Nephrology's Kidney Week 2019 investigators presented data about 3 phase 3 trials of roxadustat. The trials showed promising results about the first-in-class oral drug to treat chronic kidney disease in patients with anemia.
Number 3: First Stop Health’s inaugural 2019 Health Benefits Cost Containment Report found that reigning in benefits spending is a top priority for employers, but many lack the data necessary to make effective changes.
Number 2: Results from ISCHEMIA, presented at the American Heart Association Scientific Sessions, showed invasive procedures like stents are often no better than medical therapy and lifestyle changes at preventing a heart attack in patients with stable heart disease.
Number 1: CMS has launched the process to craft what will come after the Oncology Care Model, the 5-year alternative payment model that ends in 2021. The successor, Oncology Care First, would include a prospective, monthly population payment; accountability for total costs of care incurred over a 6-month episode; changes to make attribution more predictable, and electronic patient-reported outcomes.
To read all of these articles and more, visit ajmc.com.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More